uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Urology.ORCID iD: 0000-0002-8306-0687
2015 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 68, no 5, p. 754-755, article id S0302-2838(15)00668-5Article in journal (Refereed) Published
Abstract [en]

A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors(PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostatecancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme,number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorizedaccording to PDE5-I use within 2 yr after surgery ason demand, rehabilitation schedule(daily PDE5-I use for at least 3 mo), andno PDE5-I use. Multivariable (MVA) Coxregression models tested the association between PDE5-I and BCR. The same analyseswere repeated using the number of PDE5-I pills taken by each patient. Overall,674 patients (26.1%) received PDE5-Is. At MVA analysis, PDE5-I use, type of administra-tion schedule, and number of PDE5-I pills were not significantly associated with higherrisk of BCR (allp0.2) after accounting for multiple confounders including time from RPto PDE5-I use. While awaiting further studies, patients should not be denied PDE5-Itreatment after RP.Patient summary:Among patients treated with radical prostatectomy, phosphodies-terase type 5 inhibitor use was not associated with an increased risk of biochemicalrecurrence, regardless of the therapeutic regimen used.

Place, publisher, year, edition, pages
2015. Vol. 68, no 5, p. 754-755, article id S0302-2838(15)00668-5
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-365937DOI: 10.1016/j.eururo.2015.07.023PubMedID: 26238432OAI: oai:DiVA.org:uu-365937DiVA, id: diva2:1263380
Available from: 2018-11-15 Created: 2018-11-15 Last updated: 2019-02-28Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Stattin, Pär

Search in DiVA

By author/editor
Stattin, Pär
By organisation
Urology
In the same journal
European Urology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 9 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf